What made to order means
For compounding, a pharmacist, doctor, or registered outsourcing facility mixes or changes medicine to order. It differs from manufacturing a finished drug with FDA approval.
Source: FDA on compounding
The name registered outsourcing facility refers to a maker of batches of sterile drugs. For these drugs, sterile means free of living germs; the maker registers with FDA under rules checked November 3, 2026.
Source: FDA on compounding
Ask what would be made for you and why. Keep the full ingredient name and proposed form in your notes. If the word custom appears in an offer, ask what is actually different about the preparation. A descriptive word is not an explanation of the medical need it is meant to address.
Approval is a separate question
FDA does not approve compounded drugs or verify their safety, quality, and effectiveness before marketing, as of November 3, 2026.
Source: FDA on compounding
Ask the prescriber to explain that distinction in the context of the proposed product. An ingredient name does not tell you what review a finished drug went through. Ask about the drug itself. Keep the focus on the actual drug, with its own name and form.
The reason belongs to you
FDA describes compounding as potentially appropriate when an approved product cannot meet a person’s medical need or is not commercially available.
Source: FDA on compounding
Ask which of those issues is relevant to the proposal. For example, the question may concern the form or an ingredient, rather than the name of the pharmacy. Ask what approved option was considered and what it could not provide in your situation. Leave the explanation in the prescriber’s words when you record it.
Copies have restrictions
Federal law, as checked November 3, 2026, restricts repeated or large-scale copying of commercially available medicines through compounding.
Source: FDA on compounding
To decide whether a preparation counts as a copy, the pharmacy rule called 503A asks whether the prescriber finds a change that matters medically for the named patient. Lower cost alone is not such a change.
Source: FDA on compounding
The copy rule compares a made-to-order medicine with an available product. Ask what rule the proposed medicine relies on. A lower bill and a medical difference answer separate questions. If the explanation rests on a shortage, ask which national listing is being cited.
Know who makes it
For ordinary pharmacy compounding, section 503A of federal law ties the preparation to a named patient’s prescription. Under section 503B, a registered facility can prepare germ-free batches without a prescription for each person, as of November 3, 2026.
Source: FDA on compounding
Ask which type would supply the proposed medicine and how to check it. The pharmacy page shows the California record routes. Check the state record even if the service gives a national registration. Then ask whether the drug fits your needs. Those are separate checks.
If someone points to a recent peptide headline, take the exact policy name to the status page. That page explains the draft’s limits and what FDA approval means. Avoid trying to settle the question from a phrase clipped out of a longer notice; the conditions are part of what the notice says.